ModerateDirect oral anticoagulants (factor Xa inhibitors)×Antiepileptic, hydantoin derivative (sodium channel blocker)
Updated · Methodology
Mechanism
Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Phenytoin is one of the P-gp inducers that may lower edoxaban plasma levels (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Edoxaban also appears in the phenytoin documents. The Spanish SmPC lists it among the drugs whose levels or effects phenytoin may alter (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label lists it among the drugs whose levels phenytoin decreases (phenytoin label, US Food and Drug Administration, FDA). Neither the labels nor the European Heart Rhythm Association table says how much edoxaban levels fall (EHRA 2021).
Symptoms
The main risk is thrombosis because edoxaban works less well. In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking. The European Heart Rhythm Association guide also reports the opposite signal for direct oral anticoagulants as a group. In one case series, the risk of bleeding with phenytoin was higher. In a retrospective cohort from Taiwan, bleeding was more frequent when phenytoin was prescribed at the same time. The authors note that this result may not apply to other patient groups (EHRA 2021).
Management
Use caution when edoxaban is combined with P-glycoprotein (P-gp) inducers, phenytoin included (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). When phenytoin is started or stopped, the dose of edoxaban and other drugs on the US label's list may need adjustment (phenytoin label, US Food and Drug Administration, FDA). The dosing section of the edoxaban SmPC lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). Phenytoin may also alter the levels or effects of other oral anticoagulants: warfarin, apixaban, dabigatran and rivaroxaban (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Dilantin (extended phenytoin sodium capsules) – prescribing information (2023)– FDA label, Viatris Specialty, DailyMed setid 86dd27d1-9cee-48ae-b55d-e2d2f7dbc593, version 3, 08/2023, section 7.2 (Drugs Affected by Phenytoin)
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2